<DOC>
	<DOCNO>NCT01296815</DOCNO>
	<brief_summary>Kaposi sarcoma remain common malignancy among person HIV . Lesions localize airway may cause bleeding , pain dyspnea . New therapeutic approach local disease need . The purpose study compare effectiveness intralesional bevacizumab + HAART v HAART alone treat localize Kaposi´s sarcoma airway patient AIDS .</brief_summary>
	<brief_title>Intralesional Bevacizumab Treating AIDS-associated Kaposi´s Sarcoma Larynx , Pharynx Oral Cavity</brief_title>
	<detailed_description>Once disseminate disease exclude , histologically confirm HIV-positive patient localize Kaposi 's sarcoma airway randomize receive HAART HAART + intralesional bevacizumab . The primary outcome size lesion accord RECIST criterion . Patients HAART + bevacizumab arm undergo series 3 bevacizumab injection 5 mg/cm3 . Follow-up carry scheduled meeting office set examination every week first 8 week , every 15 day two month finally every month eight month . Size lesion assess independent observer adverse event record .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>AIDS-Related Opportunistic Infections</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Anti-Retroviral Agents</mesh_term>
	<criteria>HIV infect KS oral cavity , pharynx larynx , histopathologically confirm HIV treatmentnaïve Airway obstructive lesion Actively bleed lesion Tumorassociated oedema ulceration Gastrointestinal KS KS nonnodal viscera</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Kaposi sarcoma</keyword>
	<keyword>HIV</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>